Anti-CD20 Antibody-drug Conjugate TRS005 clinical trials
Also written TRS005.
Its developmentBy Zhejiang Teruisi Pharmaceutical, step by step3 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD20 Antibody-drug Conjugate TRS005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD20 Antibody-drug Conjugate TRS005 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TRS005
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Zhejiang Teruisi Pharmaceutical Inc. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD20 Antibody-drug Conjugate TRS005.
- Jan 2027A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.Phase 2 · Zhejiang Teruisi Pharmaceutical Inc.
Studies
Open first, then newest update. How each study uses Anti-CD20 Antibody-drug Conjugate TRS005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.Not yet recruitingPhase 2Zhejiang Teruisi Pharmaceutical Inc.NCT06886139Written as TRS005
- A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCLNot yet recruitingPhase 1/2Zhejiang Teruisi Pharmaceutical Inc.NCT07035379Written as TRS005
- A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Active, not recruitingPhase 1Zhejiang Teruisi Pharmaceutical Inc.NCT05395533Written as Recombinant CD20 monoclonal antibody-MMAE conjugte for injection